Details of the Drug Formulations

General Information of Drug (ID: DM4ONW5)

• Drug Name: Baricitinib Drug Info
• Synonyms: Baricitinib (LY3009104, INCB028050); Baricitinib [USAN:INN]; C16H17N7O2S; INCB 028050; INCB-028050; INCB028050; ISP4442I3Y; J-503551; LY-3009104; LY3009104; Olumiant (TN); UNII-ISP4442I3Y; olumiant

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[2]

• Cross-matching ID:
  PubChem CID: 44205240
  ChEBI ID: CHEBI:95341
  CAS Number: 1187594-09-7
  TTD ID: D0Y7IC
  VARIDT ID: DR00322
  INTEDE ID: DR2502
  ACDINA ID: D00859

Full List of Drug Formulations Containing This Drug

Baricitinib 1 mg tablet

Company	Formulation ID	FDA Description
Eli Lilly And	F24020	Croscarmellose Sodium; Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Ferric Oxide; Lecithin (Soya); Polyethylene Glycol; Polyvinyl Alcohol; Talc; Titanium Dioxide

Baricitinib 2 mg tablet

Company	Formulation ID	FDA Description
Eli Lilly And	F24021	Croscarmellose Sodium; Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Ferric Oxide; Lecithin (Soya); Polyethylene Glycol; Polyvinyl Alcohol; Talc; Titanium Dioxide

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] ClinicalTrials.gov (NCT04345289) Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. U.S. National Institutes of Health.